Tuberculosis is an important global public health problem. The standard therapeutic regimen includes a combination of isoniazid, rifampicin, pyrazinamide, and so on. One of the most frequent and serious side effects of these drugs is hepatotoxicity. Several studies in Asian populations have identified genetic risk factors for the development of antituberculosis drug-induced hepatotoxicity, such as drug metabolizing enzyme polymorphisms in hepatic type 2 N-acetyl transferase enzymes (NAT2), Cytochrome P450 2E1 (CYP2E1) and glutathione S-transferase (GST) genes. In this paper, we searched 2009 ~ 2014 data published in PubMed with keywords of drug-metabolising enzymes, antitubercular agents, drug-induced hepatotoxicity, drug-induced liver injury, genetic polymorphism, arylamine N-acetyltransferase , glutathione-S-transferase, cytochrome P450 2E1 and ethnic Asians limited. Antituberculosis drug-induced hepatotoxicity are higher with NAT2 slow acetylators , CYP2E1 c1/c1 and GSTM1 genotype in Asians. In addition, the individualized therapeutic doses of anti-tuberculosis drugs are needed in the future based on genetic information to achieve the greatest success outcome for each patient.